OR WAIT 15 SECS
© 2021 MJH Life Sciences and Drug Topics. All rights reserved.
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
January 15, 2021
Investigators observed that about half of patients treated with rimegepant showed a 50% or greater reduction in how many moderate-to-severe migraine days they experienced per month.
January 14, 2021
Pharmacists can provide education on migraine prophylaxis for better outcomes.
January 06, 2021
Researchers examined the 3 debated strategies for treating medication overuse headache.
January 05, 2021
A poster presented at the ASHP 2020 Midyear Clinical Meeting and Exhibition indicated opportunities for community pharmacists to improve outcomes for patients with migraines.
November 27, 2020
The pharmaceutical company has submitted a New Drug Application for dihydroergotamine mesylate for fast and lasting whole migraine relief in adults with and without aura.
November 11, 2020
Add value by optimizing medications, decreasing pill burden.
May 27, 2020
Results from a phase 3 study showed that galcanezumab-gnlm (Emgality, Eli Lilly) significantly improved work productivity and health and well-being between migraine attacks.
May 25, 2020
Migraine is one of the most common neurologic disorders in children and adolescents with a prevalence of 7.7%.
May 07, 2020
Officials with the FDA have approved celecoxib oral solution 25 mg/mL (Elyxyb, Dr. Reddy’s Laboratories) for the acute treatment of migraine with or without aura in adults.
April 02, 2020
Rimegepant (Nurtec ODT, Biohaven Pharmaceuticals) reduced monthly migraine days in patients with episode and chronic migraine in a clinical trial.
March 17, 2020
On December 23, 2019, the FDA approved ubrogepant for the acute treatment of migraine with and without aura in adult patients.
February 28, 2020
Rimegepant (Nurtec ODT, Biohaven),a fast-acting orally disintegrating tablet, delivers quick and sustained efficacy for patients with migraine.